Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 1.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $9.52 on Friday. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71. The stock has a market cap of $465.72 million, a price-to-earnings ratio of -9.43 and a beta of 0.25. The firm’s 50-day moving average is $8.42 and its 200-day moving average is $8.70.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The firm had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. During the same period in the prior year, the company earned ($0.17) earnings per share. Sell-side analysts predict that Theravance Biopharma, Inc. will post -1.04 EPS for the current fiscal year.

Institutional Trading of Theravance Biopharma

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new stake in shares of Theravance Biopharma during the 2nd quarter worth approximately $986,000. Bank of Montreal Can lifted its stake in Theravance Biopharma by 141.0% in the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after purchasing an additional 93,702 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Theravance Biopharma by 16.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock valued at $474,000 after purchasing an additional 7,509 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after purchasing an additional 91,679 shares during the period. Finally, Marshall Wace LLP lifted its holdings in Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after buying an additional 135,426 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on TBPH shares. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. TD Cowen lowered their price objective on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.